To confirm the absence of any AML-associated NPM1 and IDH1 variants in the patient, we employed dPCR for precise and sensitive detection, ensuring that no trace of these variants was present on serial bone marrow samples since the achievement of CR2. Here, IDH1 is linked to acute myeloid leukemia.